MYGN

In the past six months (April 2026 - October 2026), a significant event was the company's report of second-quarter 2026 financial results on July 30, 2026, which led to a 46.74% daily stock price decrease as performance fell short of expectations, with solid demand for Hereditary Cancer and Mental Health tests offset by volume challenges in Prenatal Health and increased payer friction, resulting in an 11% year-over-year revenue decrease and a 9% decrease in average revenue per test. Other notable events include a collaboration with SOPHiA GENETICS announced on October 8, 2026, to advance prostate genomic instability score technology; the appointment of Vishal Sikri as Executive Vice President - Commercial on September 16, 2026; a presentation at the 2026 Wells Fargo Healthcare Conference on August 27, 2026; and early vesting of some stock awards under a former commercial chief's exit deal on October 9, 2026. Over the past 12 months (October 2025 to October 2026), MYGN's stock price has decreased by 44.3%.